Analyst Price Targets — ROIV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 10:24 am | Douglas Tsao | H.C. Wainwright | $41.00 | $35.12 | TheFly | Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright |
| May 26, 2026 10:46 am | Yastin Suneja | Guggenheim | $36.00 | $29.96 | TheFly | Roivant Sciences price target raised to $36 from $30 at Guggenheim |
| May 21, 2026 12:32 pm | — | Cowen & Co. | $41.00 | $32.18 | TheFly | Roivant Sciences price target raised to $41 from $38 at TD Cowen |
| May 21, 2026 10:20 am | David Risinger | Leerink Partners | $42.00 | $32.41 | StreetInsider | Roivant Sciences (ROIV) PT Raised to $42 at Leerink |
| April 16, 2026 12:57 pm | — | Piper Sandler | $40.00 | $29.26 | TheFly | Roivant Sciences assumed with an Overweight at Piper Sandler |
| March 4, 2026 11:41 am | Douglas Tsao | H.C. Wainwright | $34.00 | $28.81 | StreetInsider | Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright |
| February 10, 2026 11:05 am | — | H.C. Wainwright | $33.00 | $27.67 | TheFly | Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright |
| February 9, 2026 1:22 pm | — | Jefferies | $30.00 | $26.45 | TheFly | Roivant Sciences price target raised to $30 from $24 at Jefferies |
| February 9, 2026 11:45 am | — | Guggenheim | $30.00 | $25.82 | TheFly | Roivant Sciences price target raised to $30 from $28 at Guggenheim |
| December 18, 2025 1:30 pm | — | Guggenheim | $28.00 | $22.30 | TheFly | Roivant Sciences price target raised to $28 from $25 at Guggenheim |
Latest News for ROIV
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition affecting skin and muscles.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ROIV.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.